glp-1 regulations Compounded GLP-1s: Why doctors worry and the FDA is cracking down Messaged provider re: GLP-1 discontinuation

Mutat Res 2015

This direct route bypasses the digestive system entirely, which makes injections a particularly valuable choice for people with conditions like Crohns disease or celiac disease

NICE guidance acknowledges that response to treatment varies between individuals

Saxenda: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, low blood sugar, upset stomach, fatigue, dizziness, abdominal pain, increased lipase (a digestive enzyme), upper abdominal pain, fever, and gastroenteritis (inflammation of the stomach and intestines)

Together, we can explore the best options for your weight loss journey

Peripheral edema : mild water retention, especially in the hands and feet